APRIUM PHARMACIE acquired by ARDIAN, BPIFRANCE & MACSF
Context
Ardian has acquired a significant minority stake in Aprium Pharmacie to support its ambitious growth plan. This investment aims to ensure the continued development of its service and consulting offerings, the expansion of its digital tools and training programs, and the ongoing development of its brand.
APRIUM PHARMACIE, which reported an EBITDA margin of LOGIN in 2023, is valued in this transaction at an EV/EBITDA multiple of LOGIN, representing a LOGIN to the average currently observed in the Healthcare & Pharma sector (14.4x).
Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.
-> Deep-dive in Healthcare & Pharma market trends
Target
The leading French network of pharmacies, operating as a high-performance integrated platform. Aprium provides independent pharmacists with a comprehensive range of services, including centralized purchasing, digital tools, marketing, and private label management to enhance profitability and patient care.
Ent. Value
LOGIN
Equity Value
LOGIN
Multiples
EV / Revenue
LOGIN
EV / EBITDA
LOGIN
EV / EBIT
LOGIN
Historical Financials (EUR)
Similar deals in Healthcare & Pharma
| Date | Acquirer | Target | Country | Sector | Deal Context |
|---|---|---|---|---|---|
| 06/2024 | L-GAM / CAPZA / IDIA CAPITAL INVESTISSEMENT | PSV GROUP | FRANCE | Health Providers | L-GAM, CAPZA, IDIA Capital Investissement, and Bpifrance are acquiring a minority stake in PSV Group from its associate physicians. The transaction allows for the entry of a consortium of minority financial partners while ensuring that the associate doctors, who remain majority shareholders, retain full operational and strategic control of the group. This strategic partnership is designed to provide the financial resources and complementary expertise required to support an ambitious new development phase. Specifically, the investment will fund the construction of a new specialized center in Lens while allowing the group to accelerate its medical project and advance its sustainable development goals. The operation focuses on maintaining the group's long-term independence and ensuring medical excellence in cancer care for the regional population. |
| 06/2024 | INTEGRAL DIAGNOSTICS LIMITED | CAPITOL HEALTH LIMITED | AUSTRALIA | Health Providers | Integral Diagnostics acquired 100% of Capitol Health via a Scheme of Arrangement. The transaction was approved by the ACCC after initial concerns, creating a highly synergistic group. The merger consolidates the fragmented Australian radiology market and provides the combined "MergeCo" with significant scale to invest in teleradiology (IDXt) and advanced AI diagnostic technologies. |
| 12/2023 | ESSLING CAPITAL | X-RAY PHOCEA | FRANCE | Health Providers | X-Ray Phocea, a leading medical imaging group in Southern France, has secured a strategic minority investment from Essling Expansion, alongside Bpifrance and SOFIPACA. Despite this new capital entry, the majority of the group�s shareholding remains in the hands of its 20 associate radiologists, preserving a practitioner-led management model. |
| 12/2023 | ANDERA PARTNERS | GROUPE IMAGERIE CARDINET | FRANCE | Health Providers | Andera Acto is providing minority financing to Imagerie Cardinet to support its next phase of expansion. The transaction is structured to allow the associate radiologists to maintain a massive majority, representing approximately 95% of the capital. This strategic funding provides the group with a development envelope of nearly EUR100 million to finance external growth. The investment strategy aims to reinforce the group's presence in the Paris region and initiate its expansion on a national scale, with several new centers expected to join by the end of the year. The operation also facilitates the entry of seven new associate radiologists into the capital structure, further strengthening the group's medical-led entrepreneurial model. |
| 10/2023 | EQT PARTNERS | VETPARTNERS | AUSTRALIA | Health Providers | EQT, through its BPEA Fund VIII, agreed to acquire VetPartners from National Veterinary Associates (NVA), a portfolio company of JAB Holding. The transaction represents a major entry for EQT into the ANZ veterinary services market, following its extensive track record with IVC Evidensia in Europe. The strategic objective is to consolidate VetPartners' leadership position through significant capital investment in digital tools, advanced diagnostic equipment, and recruitment initiatives. The deal was finalized through a fast-tracked auction process where EQT was selected as the preferred bidder over rival private equity firms. Under EQT's ownership, the group will continue its aggressive expansion across the fragmented Australasian market while enhancing its specialized veterinary training centers and managed services division (United Vets Group). |
| 08/2023 | BAIN CAPITAL | ESTIA HEALTH | AUSTRALIA | Health Providers | Following a five-month bidding process, Bain Capital has entered into a definitive Scheme Implementation Agreement to acquire 100% of the share capital of Australian aged care operator Estia Health Limited. The public-to-private transaction is structured under a board-endorsed scheme of arrangement that permits the target to distribute fully franked dividends to eligible shareholders prior to the transaction's close. For the acquirer Bain Capital, the transaction expands its dedicated healthcare portfolio, leveraging a global platform that encompasses over 175 platform investments in the medical and care sectors. The buyout secures complete operational control over a scaled Australian residential eldercare infrastructure consisting of 73 operating facilities containing over 6,500 resident places across Victoria, South Australia, New South Wales, and Queensland, backed by a workforce of lifted 8,000 employees. The post-closing corporate strategy will be executed under the continued leadership of incumbent CEO Sean Bilton. The commercial roadmap focuses on leveraging Bain Capital's institutional backing to anchor industrial market consolidation within a highly fragmented and increasingly regulated sector, optimizing corporate governance frameworks while mitigating inflationary operational pressures linked to specialized labor inputs, which account for approximately 80% of the platform's cost base. |
| 08/2023 | QUADRIVIO GROUP | THE PRIVATE CLINIC (TPC) | UNITED KINGDOM | Health Providers | Quadrivio Group has acquired a majority stake in The Private Clinic from BlueGem Capital Partners to serve as a platform for its "Silver Economy" strategy. The industrial logic is anchored in the "healthy longevity" megatrend: as the population ages, demand for aesthetic and wellness treatments among the affluent over-50s is booming. The transaction was structured as a simultaneous "Buy-and-Build" play, as TPC acquired four smaller clinics specializing in cosmetic medicine at closing to immediately scale its footprint. Quadrivio aims to use TPC to consolidate the highly fragmented aesthetic market in the UK and plans to export this business model to Italy and broader Europe, where similar consolidation opportunities exist. |
| 07/2023 | MEDIAN KLINIKEN | HESTIA ALLIANCE | SPAIN | Health Providers | MEDIAN Group, backed by Waterland Private Equity, acquired Hestia Alliance, one of Spain's largest private post-acute and mental health care providers, marking MEDIAN's first entry into the Spanish healthcare market. The transaction received regulatory approval prior to the public announcement. The acquisition is part of MEDIAN's continued internationalisation strategy following its earlier expansion into the UK through the acquisition of Priory Group in 2021. The combination of MEDIAN, Priory, and Hestia creates a pan-European post-acute and mental health platform spanning Germany, the United Kingdom, and Spain. |
| 06/2023 | ARDIAN | MON VETO | FRANCE | Health Providers | Ardian acquired a minority stake (approximately 20%) in Mon Veto through a primary capital increase. This "pure cash-in" operation was designed to strengthen the group's equity base without any cash-out for the founding veterinarians. The transaction supports Mon Veto's aggressive buy-and-build strategy in a rapidly consolidating European market. The partnership aims to accelerate the group's domestic expansion and facilitate its entry into highly fragmented international markets, such as Italy and Spain. The existing unitranche debt facility provided by Barings was maintained and extended to support future external growth, ensuring the group remains a top independent contender against large international corporate aggregators. |
| 06/2023 | PARQUEST CAPITAL | IMANEO | FRANCE | Health Providers | Parquest acquired a majority stake in the newly formed Imaneo group from its 70 associate radiologists. The transaction was the result of a competitive process involving both French and international private equity funds, as well as corporate interest from the life sciences sector. This strategic operation facilitates the merger of three independent radiology practices into a single unified platform. The associate radiologists, who were already shareholders in their respective legacy firms, reinvested significantly to retain nearly 50% of the new group's capital. The investment strategy is focused on structuring the newly created entity's management and operations to allow medical staff to focus on clinical practice while providing the financial resources for aggressive organic and external growth. A unitranche debt facility, including dedicated capital expenditure lines, was secured to fund innovation in medical technology and the acquisition of additional radiology practices across the region. |
REFERENCES
Valuation range: EV 100M - 350M EUR
EBITDA range: 5M - 25M EUR
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of APRIUM PHARMACIE by ARDIAN / BPIFRANCE / MACSF are reserved for mynth community members. Register for free to unlock full data.
Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).
Target: aprium pharmacie